Literature DB >> 19735861

Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group.

Yasushi Nagata1, Masahiro Hiraoka, Takashi Mizowaki, Yuichiro Narita, Yukinori Matsuo, Yoshiki Norihisa, Hiroshi Onishi, Hiroki Shirato.   

Abstract

PURPOSE: To recognize the current status of stereotactic body radiotherapy (SBRT) in Japan, using a nationwide survey conducted by the Japan 3-D Conformal External Beam Radiotherapy Group. METHODS AND MATERIALS: The questionnaire was sent by mail to 117 institutions. Ninety-four institutions (80%) responded by the end of November 2005. Fifty-three institutions indicated that they have already started SBRT, and 38 institutions had been reimbursed by insurance.
RESULTS: A total of 1111 patients with histologically confirmed lung cancer were treated. Among these patients, 637 had T1N0M0 and 272 had T2N0M0 lung cancer. Metastatic lung cancer was found in 702 and histologically unconfirmed lung tumor in 291 patients. Primary liver cancer was found in 207 and metastatic liver cancer in 76 patients. The most frequent schedule used for primary lung cancer was 48 Gy in 4 fractions at 22 institutions (52%), followed by 50 Gy in 5 fractions at 11 institutions (26%) and 60 Gy in 8 fractions at 4 institutions (10%). The tendency was the same for metastatic lung cancer. The average number of personnel involved in SBRT was 1.8 radiation oncologists, including 1.1 certified radiation oncologists, 2.8 technologists, 0.7 nurses, and 0.6 certified quality assurance personnel and 0.3 physicists. The most frequent amount of time for treatment planning was 61-120 min, for quality assurance was 50-60 min, and for treatment was 30 min. There were 14 (0.6% of all cases) reported Grade 5 complications: 11 cases of radiation pneumonitis, 2 cases of hemoptysis, and 1 case of radiation esophagitis.
CONCLUSION: The current status of SBRT in Japan was surveyed.

Entities:  

Mesh:

Year:  2009        PMID: 19735861     DOI: 10.1016/j.ijrobp.2009.02.087

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  46 in total

1.  Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data.

Authors:  Chad G Rusthoven; Brian D Kavanagh; Sana D Karam
Journal:  Ann Transl Med       Date:  2015-07

2.  Practical patterns for stereotactic body radiotherapy to hepatocellular carcinoma in Korea: a survey of the Korean Stereotactic Radiosurgery Group.

Authors:  Sun Hyun Bae; Mi-Sook Kim; Won Il Jang; Chul-Seung Kay; Woochul Kim; Eun Seog Kim; Jin Ho Kim; Jin Hee Kim; Kwang Mo Yang; Kyu Chan Lee; A Ram Chang; Sunmi Jo
Journal:  Jpn J Clin Oncol       Date:  2016-01-29       Impact factor: 3.019

Review 3.  Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data.

Authors:  Nitin Ohri; Adam P Dicker; Yaacov Richard Lawrence
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-01-19       Impact factor: 7.038

4.  Stereotactic ablative radiotherapy for stage I NSCLC: Recent advances and controversies.

Authors:  Suresh Senan; David A Palma; Frank J Lagerwaard
Journal:  J Thorac Dis       Date:  2011-09       Impact factor: 2.895

5.  Survey of stereotactic ablative body radiotherapy in the UK by the QA group on behalf of the UK SABR Consortium.

Authors:  G Distefano; A Baker; A J D Scott; G J Webster
Journal:  Br J Radiol       Date:  2014-03-13       Impact factor: 3.039

Review 6.  Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies.

Authors:  Jing Zhao; Ellen D Yorke; Ling Li; Brian D Kavanagh; X Allen Li; Shiva Das; Moyed Miften; Andreas Rimner; Jeffrey Campbell; Jinyu Xue; Andrew Jackson; Jimm Grimm; Michael T Milano; Feng-Ming Spring Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-03-25       Impact factor: 7.038

7.  Clinical results of accelerated hypofractionated radiotherapy for central-type small lung tumours.

Authors:  Y Hatayama; M Aoki; H Kawaguchi; K Hirose; M Sato; H Akimoto; M Tanaka; I Fujioka; K Ichise; S Ono; Y Takai
Journal:  Curr Oncol       Date:  2017-08-31       Impact factor: 3.677

Review 8.  Stereotactic radiotherapy for early lung cancer: Evidence-based approach and future directions.

Authors:  Samer Chehade; David A Palma
Journal:  Rep Pract Oncol Radiother       Date:  2014-12-12

9.  A survey of stereotactic body radiotherapy use in the United States.

Authors:  Hubert Pan; Daniel R Simpson; Loren K Mell; Arno J Mundt; Joshua D Lawson
Journal:  Cancer       Date:  2011-03-15       Impact factor: 6.860

10.  Stereotactic body radiation therapy for primary lung cancers clinically diagnosed without pathological confirmation: a single-institution experience.

Authors:  Tadamasa Yoshitake; Katsumasa Nakamura; Yoshiyuki Shioyama; Tomonari Sasaki; Saiji Ohga; Makoto Shinoto; Kotaro Terashima; Kaori Asai; Keiji Matsumoto; Yoshio Matsuo; Shingo Baba; Hiroshi Honda
Journal:  Int J Clin Oncol       Date:  2014-05-08       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.